987 related articles for article (PubMed ID: 32026255)
1. Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study.
Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
J Gen Intern Med; 2020 Jul; 35(7):2084-2093. PubMed ID: 32026255
[TBL] [Abstract][Full Text] [Related]
2. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder.
Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
Int J Geriatr Psychiatry; 2021 May; 36(5):684-696. PubMed ID: 33169433
[TBL] [Abstract][Full Text] [Related]
4. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
[TBL] [Abstract][Full Text] [Related]
5. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
6. Risk of overactive bladder associated with cholinesterase inhibitors in dementia.
Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
J Am Geriatr Soc; 2022 Mar; 70(3):820-830. PubMed ID: 34854475
[TBL] [Abstract][Full Text] [Related]
7. Risk of delirium associated with antimuscarinics in older adults: A case-time-control study.
Nishtala PS; Chyou TY
Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):883-891. PubMed ID: 35587029
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
[TBL] [Abstract][Full Text] [Related]
9. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study.
Arana A; Margulis AV; McQuay LJ; Ziemiecki R; Bartsch JL; Rothman KJ; Franks B; D'Silva M; Appenteng K; Varas-Lorenzo C; Perez-Gutthann S
Pharmacotherapy; 2018 Jun; 38(6):628-637. PubMed ID: 29723926
[TBL] [Abstract][Full Text] [Related]
10. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Matta R; Gomes T; Juurlink D; Jarvi K; Herschorn S; Nam RK
Eur Urol Focus; 2022 Sep; 8(5):1433-1440. PubMed ID: 34742663
[TBL] [Abstract][Full Text] [Related]
11. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
12. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
Rangganata E; Widia F; Rahardjo HE
Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
[TBL] [Abstract][Full Text] [Related]
13. Antimuscarinic use and discontinuation in an older adult population.
Vouri SM; Schootman M; Strope SA; Xian H; Olsen MA
Arch Gerontol Geriatr; 2019; 80():1-11. PubMed ID: 30268971
[TBL] [Abstract][Full Text] [Related]
14. Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia.
Masurkar PP; Chatterjee S; Sherer JT; Aparasu RR
Drugs Aging; 2021 Jul; 38(7):593-602. PubMed ID: 34027602
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V; Hallas J; Linder M; Margulis AV; Suehs BT; Arana A; Phiri K; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Xu Y; Kristiansen NS; Appenteng K; de Vogel S; Seeger JD;
Drug Saf; 2021 Aug; 44(8):899-915. PubMed ID: 34236595
[TBL] [Abstract][Full Text] [Related]
16. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease.
Abraham DS; Pham Nguyen TP; Newcomb CW; Gray SL; Hennessy S; Leonard CE; Liu Q; Weintraub D; Willis AW
Parkinsonism Relat Disord; 2023 Oct; 115():105822. PubMed ID: 37713748
[TBL] [Abstract][Full Text] [Related]
18. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
[TBL] [Abstract][Full Text] [Related]
20. Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder.
Suehs BT; Davis C; Ng DB; Gooch K
Drugs Aging; 2017 Jul; 34(7):535-543. PubMed ID: 28540648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
